Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models

• Bénédicte Menn,

  Affiliation Neurokin S.A., Institut de Neurobiologie de la Méditerranée, Marseille, France

  ⨯
• Stéphane Bach,

  Affiliation USR3151, CNRS, Station Biologique de Roscoff, Roscoff, France

  ⨯
• Teri L. Blevins,

  Affiliation Efficacy Pharmacology, MDS Pharma Services, Bothell, Washington, United States of America

  ⨯
• Mark Campbell,

  Affiliation Efficacy Pharmacology, MDS Pharma Services, Bothell, Washington, United States of America

  ⨯
• Laurent Meijer,

  Affiliation USR3151, CNRS, Station Biologique de Roscoff, Roscoff, France

  ⨯
• Serge Timsit

  * E-mail: serge.timsit@chu-brest.fr

  Affiliation Département de Neurologie, CHRU Brest, Faculté de Médecine et des Sciences de la Santé de Brest, Brest, France

  ⨯